apoCIII inhibitors
apoCIII inhibitors has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 27, 2026: “Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease”.
1 paper studies it1 findingUpdated
See all 1 papers on apoCIII inhibitors
What did studies of apoCIII inhibitors find?
1Studies of apoCIII inhibitors measured one outcome, remnant cholesterol.
Remnant cholesterol
downin humans1
1 study
Remnant cholesterol
downin humans1
apoCIII inhibitors decrease remnant cholesterol in individuals with elevated plasma triglyceride levels up to 10 mmol/L (880 mg/dL) (50-80%).
“apoCIII and ANGPTL3 and 4 inhibitors and FGF21 analogues lower remnant cholesterol levels by 50-80%”
Reviewin individuals with elevated plasma triglyceride levels up to 10 mmol/L (880 mg/dL)
Expert opinion on therapeutic targets